Gyre Therapeutics (Gyre Therapeutics) Equity-to-Asset : -0.14 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Gyre Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-15.8 Mil. Gyre Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $116.5 Mil. Therefore, Gyre Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.14.

The historical rank and industry rank for Gyre Therapeutics's Equity-to-Asset or its related term are showing as below:

GYRE' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.14 Med: 0.5 Max: 0.86
Current: -0.14

During the past 3 years, the highest Equity to Asset Ratio of Gyre Therapeutics was 0.86. The lowest was -0.14. And the median was 0.50.

GYRE's Equity-to-Asset is ranked worse than
86.07% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs GYRE: -0.14

Gyre Therapeutics Equity-to-Asset Historical Data

The historical data trend for Gyre Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Equity-to-Asset Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Equity-to-Asset

0.86

0.50

-0.14

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
Equity-to-Asset	0.86	0.50	-0.14

Competitive Comparison of Gyre Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Gyre Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Equity-to-Asset falls into.

Gyre Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Gyre Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-15.828	/	116.539
	=	-0.14

Gyre Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-15.828	/	116.539
	=	-0.14

Gyre Therapeutics (NAS:GYRE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Gyre Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023